Sarepta Therapeutics shares plunge as gene therapy trial falls short of primary goal
By Eleanor Laise
Company plans to seek label expansion for Duchenne muscular dystrophy treatment
Sarepta Therapeutics Inc. shares (SRPT) dropped more than 40% premarket on Tuesday after the company said a trial of its gene therapy for Duchenne muscular dystrophy fell short of its main goal.
The therapy, Elevidys, helped patients' movement and walking ability but failed to produce a statistically significant improvement versus placebo in an ambulatory assessment after 52 weeks of treatment, Sarepta said in a release Monday.
The trial involved patients age 4 through 7 years with Duchenne muscular dystrophy, a genetic disorder that can cause severe muscle weakness, with symptoms starting in early childhood.
Based on the overall trial results, Sarepta said it plans to seek a label expansion so that Elevidys can treat all patients. The U.S. Food and Drug Administration in June approved Elevidys for treatment of patients age 4 through 5 years. The trial results support the conclusion that Elevidys "modifies the trajectory of Duchenne and benefits patients across age groups living with this ferociously degenerative disease," Doug Ingram, Sarepta's president and CEO, said in a statement.
The trial data were "extremely disappointing," Leerink Partners analysts wrote in a note Monday, but "we are not writing off the FDA's historical flexibility" in Duchenne muscular dystrophy. The analysts maintained an outperform rating on Sarepta shares but cut their price target to $130, from $185.
Sarepta stock is down 16.9% in the year to date, while the S&P 500 SPX has gained 8.5%.
-Eleanor Laise
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
10-31-23 0825ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks